StockData
Xeris Biopharma Holdings, Inc. logo

Xeris Biopharma Holdings, Inc. (XERS) stock

XERSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$16.62−0.37 (-2.18%)

Close on Nov 19, 2026Market cap $3.03BP/E –Yield –

Xeris Biopharma revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Xeris Biopharma's revenue for the twelve months ending Jun 30, 2026 was $335.41M, up 36.3% year over year. For fiscal 2025 it was $291.85M, up 43.7% from the year before. The highest annual figure on record is $291.85M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$291.85M+43.7%
FY2024Dec 31, 2024$203.07M+23.9%
FY2023Dec 31, 2023$163.91M+48.7%
FY2022Dec 31, 2022$110.25M+122.3%
FY2021Dec 31, 2021$49.59M+142.7%
FY2020Dec 31, 2020$20.44M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$92.10M+28.7%
Q1 FY2026Mar 31, 2026$83.13M+38.3%
Q4 FY2025Dec 31, 2025$85.81M+42.8%
Q3 FY2025Sep 30, 2025$74.38M+37.1%
Q2 FY2025Jun 30, 2025$71.54M+48.8%
Q1 FY2025Mar 31, 2025$60.12M+47.9%
Q4 FY2024Dec 31, 2024$60.10M+35.4%
Q3 FY2024Sep 30, 2024$54.27M+12.3%
Q2 FY2024Jun 30, 2024$48.07M+26.5%
Q1 FY2024Mar 31, 2024$40.64M+22.4%
Q4 FY2023Dec 31, 2023$44.39M+33.9%
Q3 FY2023Sep 30, 2023$48.32M+62.6%
Q2 FY2023Jun 30, 2023$38.01M+50.2%
Q1 FY2023Mar 31, 2023$33.20M+50.4%
Q4 FY2022Dec 31, 2022$33.14M+54.7%
Q3 FY2022Sep 30, 2022$29.73M+168.8%
Q2 FY2022Jun 30, 2022$25.31M+184.1%
Q1 FY2022Mar 31, 2022$22.07M+169.3%
Q4 FY2021Dec 31, 2021$21.43M+190.8%
Q3 FY2021Sep 30, 2021$11.06M+17.6%
Q2 FY2021Jun 30, 2021$8.91M–
Q1 FY2021Mar 31, 2021$8.20M–
Q4 FY2020Dec 31, 2020$7.37M–
Q3 FY2020Sep 30, 2020$9.40M–

More Xeris Biopharma figures

See a number that looks wrong?